Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 2:
3. The method according to claim 2, in which said at least one immunoglobulin single variable domain essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
(i) CDR1 is chosen from the group consisting of:
(a) SEQ ID NO: 73; and
(b) amino acid sequences that have 4, 3, 2, or 1 amino acid difference(s) with SEQ ID NO: 73, wherein
at position 2 the T has been changed into S;
at position 7 the D has been changed into N;
at position 8 the S has been changed into A; and/or
at position 10 the A has been changed into G;, and/or
(ii) CDR2 is chosen from the group consisting of:
(c) SEQ ID NO: 90; and
(d) amino acid sequences that have 4, 3, 2, or 1 amino acid difference(s) with SEQ ID NO: 90, wherein
at position 1 the A has been changed into H, T, or G;
at position 2 the I has been changed into M;
at position 3 the T has been changed into S;
at position 6 the G has been changed into S;
at position 7 the S has been changed into R, or G; and/or
at position 8 the P has been changed into S, T, or R;, and/or
(iii) CDR3 is chosen from the group consisting of:
(e) SEQ ID NO: 118; and
(f) amino acid sequences that have 2, or 1 amino acid difference(s) with SEQ ID NO: 118, wherein
at position 9 the A has been changed into P;
at position 11 the M has been changed into L, K, R, or Q; and/or
at position 12 the D has been changed into N.